jetcityimage/iStock Editorial via Getty Images
Donanemab, which is marketed under the brand name Kisunla, has been approved in the US and Japan this year. It competes against Biogen (BIIB) and Eisai’s (OTCPK:ESALF)(OTCPK:ESAIY) Leqembi (lecanemab).
More on Eli Lilly
- Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
- Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
- Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
- Weight loss drugs have one big issue; These companies want to fix it
- FDA to review removal of Eli Lilly weight loss drug from shortage list